Pharmafile Logo
Pharmafocus logo
Advanced Search

ViiV Healthcare

Showing 15 posts of 22 posts found.

Vaccine image

ViiV Healthcare gains positive CHMP opinion for cabotegravir for HIV prevention

July 24, 2023
Medical Communications CHMP, EMA, HIV, HIV/AIDS, ViiV Healthcare, cabotegravir

GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal …

News

GSK’s ViiV and Halozyme to collaborate on ‘ultra-long acting’ HIV drugs

June 22, 2021
Manufacturing and Production GSK, HIV, ViiV Healthcare

ViiV Healthcare, the specialist HIV company majority owned by GlaxoSmithKline (GSK), is to collaborate with Halozyme Therapeutics, giving it exclusive …

News
landing-hero-images1

ViiV presents positive long-term data for combined HIV treatment

March 8, 2021
Sales and Marketing HIV, ViiV Healthcare

ViiV Healthcare has presented positive long-term data from its global Phase IIIb ATLAS-2M study of the first complete, long-acting regimen …

News
landing-hero-images1

ViiV’s long-acting HIV drug Cabenuva gets FDA approval

January 22, 2021
Medical Communications HIV, ViiV Healthcare

The FDA has approved ViiV’s Cabenuva, the first and only complete long-acting regimen for the treatment of HIV-1 infection in …

News
viiv

ViiV and Chelsea & Westminster Hospital launch digital service for HIV patients

January 18, 2021
Sales and Marketing HIV, ViiV Healthcare

Global specialist HIV company ViiV Healthcare and Chelsea and Westminster Hospital NHS Foundation Trust have launched a new service, Klick, …

News
shutterstock_212432119

ViiV’s two-drug regimen proves non-inferior in treatment-naive HIV-1

October 5, 2020
Research and Development, Sales and Marketing HIV-1, ViiV Healthcare, pharma

ViiV Healthcare has taken the opportunity at the HIV Glasgow 2020 Virtual Congress to unveil three-year Phase 3 data from …

News
viiv

ViiV Healthcare secures FDA approval for Rukobia combo in multidrug-resistant HIV-1

July 6, 2020
Sales and Marketing FDA, HIV, ViiV Healthcare

ViiV Healthcare, the HIV specialist majority owned by GSK which also counts Shionogi and Pfizer among its shareholders, has secured …

News
landing-hero-images1

Japan welcomes approval of ViiV’s Dovato for HIV-1

January 17, 2020
Medical Communications, Sales and Marketing Dovato, Japan, ViiV Healthcare, pharma

Japan’s Ministry of Health, Labour and Welfare (MHLW) has awarded marketing approval to ViiV Healthcare, a subsidiary of GSK, for …

News
1920px-hiv-budding-color

GSK’s two drug HIV regimen effective when administered every two months

August 22, 2019
Research and Development AIDS, GSK, HIV, ViiV Healthcare, viral supression

GSK’s long-acting, two-drug HIV regimen was as effective in supressing patient’s viral loads when administered every two months (eight weeks), …

News
landing-hero-images1

ViiV’s Dovato approved in Europe as treatment option for HIV-1

July 3, 2019
Research and Development, Sales and Marketing Dovato, GSK, HIV, ViiV Healthcare, pharma

ViiV Healthcare, the specialist HIV firm majority owned by GSK, is celebrating the news that the European Commission has chosen …

News

ViiV Healthcares scores first twin-drug FDA approval for untreated HIV-1

April 9, 2019
Manufacturing and Production, Research and Development GSK, HIV, ViiV Healthcare, pharma

ViiV Healthcare, the pharmaceutical firm owned by Shionogi, Pfizer and predominantly GSK, has announced its two-drug HIV regimen Dovato (dolutegravir …

News

Janssen and ViiV’s monthly injectable HIV combo proves non-inferior to daily standard of care

August 15, 2018
Research and Development HIV, Janssen, ViiV Healthcare, pharma

Janssen and GSK’s ViiV Healthcare have unveiled strong new Phase 3 data on its two-drug regimen, injected once a month, …

News
landing-hero-images1

ViiV’s two-drug regimen gets EU approval for HIV-1

May 22, 2018
Manufacturing and Production, Sales and Marketing EMA, EU, Europe, HIV, Juluca, ViiV Healthcare, pharma

ViiV Healthcare has announced that its HIV therapy Juluca (dolutegravir/rilpivirine) has been awarded marketing authorisation in the EU from the …

News
gilead-sciences

FDA approves Gilead’s Biktarvy for HIV as Viiv Healthcare launches patent lawsuit

February 8, 2018
Sales and Marketing Biktarvy, FDA, GSK, Gilead, HIV, Pfizer, Shionogi, US, ViiV Healthcare, descovy, pharma

Gilead has announced that its daily single-tablet therapy Biktarvy has received FDA approval for HIV-1 infection.

News
gsk_boronia_australia

FDA approves first-ever two-drug HIV regimen, GSK’s Juluca

November 22, 2017
Research and Development, Sales and Marketing AIDS, FDA, GSK, Gilead, GlaxoSmithKilne, HIV, Juluca, ViiV Healthcare, pharma

GlaxoSmithKline has announced that the FDA has awarded US marketing authorisation to the first two-drug regimen in the treatment of …

News

Latest content

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share

September 27, 2023

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023